For the quarter ending 2026-03-31, RLYB had $9,925K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -8,278 | -5,852 | 16,016 | -19,142 |
| Depreciation and amortization | 3 | 3 | 35 | 54 |
| Net accretion of discounts/premiums on debt securities | -51 | -97 | -113 | -363 |
| Share-based compensation | 613 | 774 | 1,047 | 3,493 |
| Gain on sale of joint venture | - | 0 | 22,350 | - |
| Loss on investment in joint venture | 0 | 0 | 0 | -874 |
| Prepaid expenses, operating lease right-of-use assets and other current assets | 155 | -815 | 773 | 2,085 |
| Accounts payable | 814 | -143 | 150 | -159 |
| Accrued expenses and operating lease liabilities | -712 | 33 | -350 | -832 |
| Deferred revenue | -212 | -212 | -212 | -424 |
| Net cash used in operating activities | -7,978 | -4,679 | -6,550 | -18,584 |
| Purchases of marketable securities | 0 | 7,075 | 738 | 9,884 |
| Proceeds from maturities of marketable securities | 17,900 | 11,000 | 9,965 | 25,500 |
| Proceeds from sale of common stock received from sale of joint venture | - | 0 | 20,000 | - |
| Investment in joint venture | 0 | 0 | 0 | 1,500 |
| Net cash provided by investing activities | 17,900 | 3,925 | 29,227 | 14,116 |
| Proceeds from the issuance of common stock under the stock purchase plan | - | - | 0 | 10 |
| Proceeds from the issuance of common stock from exercise of stock options | 3 | 0 | 0 | 0 |
| Proceeds from the issuance of common stock under the stock purchase plan | - | 16 | - | - |
| Payments of offering costs | - | 0 | 0 | 0 |
| Net cash provided by financing activities | 3 | 6 | 0 | 10 |
| Net increase in cash and cash equivalents | 9,925 | -748 | 22,677 | -4,458 |
| Cash and cash equivalents beginning of period | 31,374 | 32,122 | 13,903 | - |
| Cash and cash equivalents end of period | 41,299 | 31,374 | 32,122 | - |
Rallybio Corp (RLYB)
Rallybio Corp (RLYB)